Catheter Ablation in Arrhythmogenic Right Ventricular Cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited myocardial disease characterized by ventricular arrhythmias, progressive structural change, and an increased risk of sudden cardiac death. Although the right ventricle is often prominently affected, left-dominant and biventricular forms are increasingly recognized. This broader disease spectrum has important implications for electrophysiological assessment and ablation planning.
Catheter ablation can reduce recurrent ventricular tachycardia (VT), implantable cardioverter-defibrillator (ICD) therapies, and electrical storm. It does not remove the underlying cardiomyopathic substrate or replace protection from sudden death when an ICD is indicated. The central clinical question is therefore not simply whether to ablate, but when to intervene and how to match the procedure to the distribution and evolution of scar.
Clinicians assessing these patients benefit from integrating symptoms, arrhythmia burden, ventricular function, cardiac magnetic resonance imaging, genetic findings, exercise history, and prior therapies. The Journal of Arrhythmia provides a useful setting for following evolving evidence in ventricular arrhythmia management, electrophysiology, and device therapy.
Why Timing Matters
ARVC-related VT usually reflects progressive fibro-fatty replacement and re-entry around areas of abnormal myocardium. Early in the disease, the arrhythmogenic substrate may be relatively localized and accessible from the endocardium. With progression, scar can extend through the ventricular wall and involve the epicardium, making a limited endocardial procedure less likely to provide durable control.
Ablation is generally considered when sustained monomorphic VT recurs, causes significant symptoms, triggers appropriate ICD shocks, or persists despite antiarrhythmic medication. Electrical storm or incessant VT may require urgent stabilization and expedited ablation. The decision must account for hemodynamic tolerance, ventricular function, renal and hepatic status, anesthesia risk, and the patient’s ability to undergo a potentially staged procedure.
Waiting for numerous ICD shocks is not always a sound strategy. Repeated shocks can impair quality of life and may indicate an expanding substrate. At the same time, prophylactic ablation in an asymptomatic patient without documented VT has not become routine practice. In most cases, intervention is guided by clinically meaningful ventricular arrhythmia rather than imaging abnormalities alone.
Selecting Patients For Intervention
Before ablation, the arrhythmia should be characterized carefully. Twelve-lead ECG documentation of clinical VT is highly valuable because it helps distinguish a right ventricular outflow tract pattern from scar-related re-entry and provides a reference for pace mapping. ICD electrograms, ambulatory monitoring, exercise testing, and device interrogation may reveal additional morphologies or frequent premature ventricular complexes that contribute to arrhythmia initiation.
The procedural discussion should occur within a multidisciplinary team that includes inherited cardiomyopathy specialists, electrophysiologists, imaging experts, heart failure clinicians, and genetic counselors when appropriate. A review of the journal information can help clinicians identify the publication’s scope and educational resources relevant to complex rhythm disorders.
Exercise exposure deserves specific attention. High-intensity endurance or competitive exercise may accelerate disease expression and increase ventricular arrhythmia risk in susceptible individuals. Exercise restriction is part of disease management, but it does not eliminate an established scar substrate. Patients need a coordinated plan covering lifestyle, medication, ICD programming, family evaluation, and follow-up after ablation.
Mapping The Arrhythmogenic Substrate
A comprehensive electrophysiology study usually begins with activation mapping during VT when the rhythm is tolerated. Critical isthmuses can be identified through entrainment, diastolic potentials, late potentials, and local electrogram characteristics. When VT is unstable or cannot be induced, substrate mapping in sinus rhythm becomes central.
Three-dimensional electroanatomic mapping defines low-voltage regions, abnormal potentials, conduction slowing, and channels within scar. In ARVC, the substrate commonly involves the right ventricular free wall, outflow tract, and inferior or diaphragmatic regions. The epicardial surface may show a broader or earlier area of abnormality than the endocardium. Cardiac magnetic resonance imaging can support this assessment, although image registration and the distinction between disease scar and procedural injury require care.
Ablation endpoints should be explicit. Depending on the strategy, these may include elimination of clinical VT, noninducibility of sustained VT, abolition of abnormal electrograms, and modification or isolation of late-potential channels. Noninducibility is useful but imperfect: pharmacological conditions, autonomic tone, anesthesia, and evolving disease can influence inducibility. A technically successful procedure therefore requires long-term clinical surveillance rather than reliance on a single endpoint.
Choosing Endocardial And Epicardial Access
An endocardial-first approach may be reasonable when imaging, ECG features, and mapping suggest a predominantly endocardial right ventricular substrate. It can reduce procedural complexity and avoid the specific risks associated with pericardial access. However, an endocardial-only procedure may leave important epicardial circuits untreated when the disease has penetrated the full ventricular wall.
Combined endocardial and epicardial ablation is often considered for recurrent VT, extensive scar, failed prior endocardial ablation, or electrocardiographic and imaging features suggesting epicardial involvement. Epicardial mapping can identify low-voltage areas, fractionated electrograms, and delayed potentials that correspond to critical circuits. In experienced centers, a combined approach may improve arrhythmia control, though it increases procedural burden.
Pericardial bleeding, coronary artery injury, phrenic nerve damage, and pericarditis are among the complications requiring careful prevention and monitoring. Coronary angiography or imaging may be needed before delivering energy near coronary vessels. Anticoagulation management, temperature monitoring, and access planning should be individualized, especially when an ICD lead, prior surgery, or significant ventricular dysfunction complicates the procedure.
| Clinical situation | Common procedural emphasis | Key consideration |
|---|---|---|
| First sustained VT with a localized substrate | Endocardial mapping and ablation | Confirm the clinical VT and assess for deeper scar |
| Recurrent ICD shocks despite medication | Detailed substrate mapping, often with broader lesion strategy | Reduce shock burden while preserving ventricular function |
| Failed endocardial ablation | Epicardial reassessment or combined approach | Look for residual epicardial channels and alternate circuits |
| Electrical storm or incessant VT | Urgent stabilization plus targeted ablation | Treat triggers, optimize ICD programming, and manage sympathetic drive |
| Advanced biventricular disease | Individualized ablation with heart failure planning | Ablation may palliate VT but does not reverse pump failure |
Integrating Medication And Device Therapy
Antiarrhythmic drugs may reduce VT recurrence before ablation, stabilize a patient for a procedure, or support rhythm control afterward. Beta-blockers are commonly used, while agents such as sotalol or amiodarone require individualized consideration of ventricular function, organ toxicity, age, and interactions. Drug therapy should be reviewed rather than continued automatically when adverse effects outweigh benefit.
An ICD remains central for patients who meet established primary- or secondary-prevention criteria. Ablation aims to reduce recurrent VT and inappropriate or appropriate shocks; it is not a substitute for defibrillator protection. Programming choices, detection intervals, antitachycardia pacing, and discrimination algorithms can substantially affect the patient’s experience while the substrate is being treated.
Ablation may be particularly valuable when recurrent VT causes repeated shocks despite optimized medication and device programming. In patients with advanced ventricular dysfunction, however, the electrophysiology plan must be aligned with heart failure treatment, mechanical support assessment, or transplant evaluation when appropriate. Controlling VT is clinically important, but it should not delay recognition of progressive pump failure.
Long-Term Follow-Up After Ablation
Recurrence after ablation is possible because ARVC is a progressive disease. A new VT morphology may represent a previously untreated circuit, disease extension, or recovery of conduction across a partially modified region. Recurrence does not automatically mean the first procedure was unsuccessful; it should prompt a structured review of the original maps, lesion set, ICD recordings, and updated imaging.
Follow-up commonly includes device interrogation, symptom review, ambulatory monitoring when indicated, ECG assessment, and periodic evaluation of ventricular function. The intensity and timing depend on arrhythmia history, genetic and phenotypic risk, ventricular performance, and treatment response. ICD shocks, syncope, sustained palpitations, and escalating premature ventricular complexes warrant prompt reassessment.
Repeat ablation can be appropriate when recurrent monomorphic VT remains clinically significant and the patient’s overall condition permits another procedure. The second intervention should be guided by the new clinical VT and prior lesion distribution rather than simply repeating the original lesion set. Long-term care also includes family screening, psychosocial support, medication review, and continued counseling about strenuous exercise.
Practical Principles For Clinical Planning
A consistent workflow helps balance the benefits of arrhythmia suppression against procedural risks. Important principles include:
- Confirm the clinical VT pattern with surface ECG, ICD electrograms, or reliable rhythm documentation whenever possible.
- Use cardiac imaging and electroanatomic mapping together to estimate endocardial, intramural, and epicardial substrate.
- Consider ablation after meaningful sustained VT, recurrent ICD therapies, electrical storm, or medication failure rather than waiting for uncontrolled shock burden.
- Treat ablation as part of a wider plan that includes ICD protection, device programming, medication, exercise counseling, and heart failure assessment.
- Refer complex or recurrent cases to centers experienced in inherited cardiomyopathy, epicardial access, and ventricular tachycardia ablation.
The evidence base continues to develop through registries, comparative studies, and long-term follow-up. Clinicians and trainees can consult the journal’s author guidance when preparing original research, reviews, or clinical perspectives that address procedural outcomes and inherited arrhythmia care.
Timing should be individualized, but the underlying logic is clear: intervene when VT becomes clinically consequential, map beyond the visible surface of the disease, and anticipate that the substrate may evolve. A carefully selected endocardial or combined endocardial–epicardial strategy can reduce arrhythmia burden while preserving the broader goals of sudden-death prevention and cardiomyopathy management. Access current evidence and clinical discussions through Journal of Arrhythmia to support informed electrophysiology practice.